Highlight therapeutics stock
WebHighlight Therapeutics SL Biotechnology Research Unlocking the potential of immuno-oncology Follow View all 16 employees About us Highlight, formerly known as Bioncotech … WebFeb 4, 2024 · Highlight Therapeutics's latest funding round was a Series D for $27.17M on February 4, 2024. View all funding This profile has not been claimed. You're more than your latest funding, tell our customers your company's story. Submit Your Analyst Briefing Highlight Therapeutics Investors 5 Investors Highlight Therapeutics has 5 investors.
Highlight therapeutics stock
Did you know?
WebApr 17, 2024 · MADRID, Spain, April 17, 2024 (GLOBE NEWSWIRE) -- Highlight Therapeutics, a clinical-stage biopharmaceutical company developing RNA-based therapies against … WebDec 2, 2024 · Highlight Therapeutics, formerly known as Bioncotech Therapeutics, is a private, clinical-stage company dedicated to unlocking the full potential of immuno-oncology.
WebMar 15, 2024 · Highlight Therapeutics is a private, clinical-stage company dedicated to unlocking the full potential of immuno-oncology. Our lead drug candidate BO-112 is a … WebApr 17, 2024 · Highlight Therapeutics also announced that clinical trials of its lead product candidate BO-112 will be classified numerically under the umbrella name Spotlight for …
WebJan 2, 2024 · The company has been listed on the Spanish Stock Exchange since 2015 and has two compounds in Phase II clinical trials: iadademstat, an oncology asset with orphan … Web2 days ago · Apr 13, 2024 (The Expresswire) -- The "Silent Cancer Therapeutics Market" Size, Trends and Forecasts (2024-2030)â , provides a comprehensive analysis of the...
WebG1 Therapeutics Provides Fourth Quarter and Full Year 2024 Financial Results and Operational Highlights. GlobeNewswire. Feb-28-23 02:10PM: ... G1 Therapeutics stock plummets 50% after trial cut short for cancer drug. …
WebSep 30, 2024 · Highlight Therapeutics Study Details Tabular View No Results Posted Disclaimer How to Read a Study Record Study Description Go to Brief Summary: This is a phase 2, single arm, open label, adaptive design study to determine the preliminary anti-tumor activity and confirm the safety of IT BO-112 in combination with intravenous (IV) … reading spanish onlineWebCall for general extraordinary shareholders’ meeting of the company highlight therapeutics, S.L. June 27, 2024, at 12:30 1st June 2024 More Info Highlight Therapeutics announces follow-up results from Phase 2b study … reading spark on scannerWebApr 10, 2024 · The trading price of Seres Therapeutics Inc. (NASDAQ:MCRB) closed higher on Thursday, April 06, closing at $5.77, 2.85% higher than its previous close. In examining the 52-week price action we see that the stock hit a 52-week high of $9.49 and a 52-week low of $2.50. Over the past month, the stock has lost -2.86% in value. reading spark plugs for timingWebMar 15, 2024 · Highlight Therapeutics is a private, clinical-stage company dedicated to unlocking the full potential of immuno-oncology. Our lead drug candidate BO-112 is a best-in-class RNA-based therapy which has been demonstrated to initiate a powerful immune response, leveraging a unique multi-target approach to turn 'cold' tumors 'hot' and … reading sparksWebApr 10, 2024 · About TPST. Tempest Therapeutics Inc., a clinical-stage oncology company, engages in developing small molecule therapeutics to treat cancer. The company's two clinical programs are TPST-1495, a dual antagonist of EP2 and EP4, receptors of prostaglandin E2, and is currently in a Phase 1 trial in solid tumors; and TPST-1120, a … reading specialist certificationWebMar 14, 2024 · BOSTON, March 14, 2024 (GLOBE NEWSWIRE) -- Tango Therapeutics, Inc. (NASDAQ: TNGX) today announced the acceptance of two oral and two poster presentations at the American Association for Cancer Research (AACR) 2024 Annual Meeting, taking place from April 14-19, 2024 in Orlando, Florida.Abstract titles, presentation information and … reading spcaWebApr 13, 2024 · Highlight Therapeutics, formerly known as Bioncotech Therapeutics, is a private, clinical-stage company dedicated to unlocking the full potential of immuno … reading spark on scanner graph